

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM349301

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	Security Agreement		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Dendreon Pharmaceuticals, Inc.		07/24/2015	CORPORATION: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Barclays Bank PLC, as Collateral Agent		
<b>Street Address:</b>	745 Seventh Avenue		
<b>City:</b>	New York		
<b>State/Country:</b>	NEW YORK		
<b>Postal Code:</b>	10019		
<b>Entity Type:</b>	Bank: UNITED STATES		
<b>PROPERTY NUMBERS Total: 17</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	3228929	ANTIGEN DELIVERY CASSETTE	
<b>Registration Number:</b>	2188041	DACs	
<b>Registration Number:</b>	2530065	DENDREON	
<b>Registration Number:</b>	2465920	DENDREON	
<b>Registration Number:</b>	3616391	DENDREON	
<b>Registration Number:</b>	3581626	DENDREON	
<b>Registration Number:</b>	4099276	DENDREON	
<b>Registration Number:</b>	3982430	DENDREON TARGETING CANCER, TRANSFORMING	
<b>Registration Number:</b>	3726707	DENDREON TARGETING CANCER, TRANSFORMING	
<b>Registration Number:</b>	2545242	PROVENGE	
<b>Registration Number:</b>	3581625		
<b>Registration Number:</b>	4158044		
<b>Serial Number:</b>	85780732	INTELLIVENGE	
<b>Serial Number:</b>	85657232	NEUVENGE	
<b>Serial Number:</b>	85960682	POWERED BY INTELLIVENGE	
<b>Serial Number:</b>	85960680	THE DIFFERENCE IS PERSONAL	
<b>Serial Number:</b>	85960681	THE DIFFERENCE IS PERSONAL	
<b>CORRESPONDENCE DATA</b>			
<b>TRADEMARK</b>			

OP \$440.00 3228929

**Fax Number:**

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Email:** marina.kelly@thomsonreuters.com

**Correspondent Name:** Elaine Carrera, Legal Assistant

**Address Line 1:** 80 Pine Street

**Address Line 2:** c/o Cahill Gordon & Reindel LLP

**Address Line 4:** New York, NEW YORK 10005

<b>NAME OF SUBMITTER:</b>	Elaine Carrera, Legal Assistant
---------------------------	---------------------------------

<b>SIGNATURE:</b>	/Marina Kelly, Thomson Reuters/
-------------------	---------------------------------

<b>DATE SIGNED:</b>	07/27/2015
---------------------	------------

**Total Attachments: 8**

source=US - Trademark Security Agreement (Dendreon)#page1.tif

source=US - Trademark Security Agreement (Dendreon)#page2.tif

source=US - Trademark Security Agreement (Dendreon)#page3.tif

source=US - Trademark Security Agreement (Dendreon)#page4.tif

source=US - Trademark Security Agreement (Dendreon)#page5.tif

source=US - Trademark Security Agreement (Dendreon)#page6.tif

source=US - Trademark Security Agreement (Dendreon)#page7.tif

source=US - Trademark Security Agreement (Dendreon)#page8.tif

### RECORDATION FORM COVER SHEET TRADEMARKS ONLY

To the Director of the U. S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

**1. Name of conveying party(ies):**

Dendreon Pharmaceuticals, Inc.

- Individual(s)
- Partnership
- Corporation- State: DE
- Other \_\_\_\_\_
- Association
- Limited Partnership

Citizenship (see guidelines) USA

Additional names of conveying parties attached?  Yes  No

**3. Nature of conveyance/Execution Date(s) :**

Execution Date(s) July 24, 2015

- Assignment
- Security Agreement
- Other \_\_\_\_\_
- Merger
- Change of Name

**2. Name and address of receiving party(ies)**

Additional names, addresses, or citizenship attached?  Yes  No

Name: Barclays Bank PLC, as Collateral Agent

Street Address: 745 Seventh Avenue

City: New York

State: NY

Country: USA Zip: 10019

- Individual(s) Citizenship \_\_\_\_\_
- Association Citizenship \_\_\_\_\_
- Partnership Citizenship \_\_\_\_\_
- Limited Partnership Citizenship \_\_\_\_\_
- Corporation Citizenship \_\_\_\_\_
- Other Bank Citizenship USA

If assignee is not domiciled in the United States, a domestic representative designation is attached:  Yes  No  
(Designations must be a separate document from assignment)

**4. Application number(s) or registration number(s) and identification or description of the Trademark.**

A. Trademark Application No.(s) Text

See Schedule A

B. Trademark Registration No.(s)

See Schedule A

Additional sheet(s) attached?  Yes  No

C. Identification or Description of Trademark(s) (and Filing Date if Application or Registration Number is unknown):

**5. Name & address of party to whom correspondence concerning document should be mailed:**

Name: Elaine Carrera, Legal Assistant

Internal Address: \_\_\_\_\_

Street Address: c/o Cahill Gordon & Reindel LLP  
80 Pine Street

City: New York

State: NY Zip: 10005

Phone Number: (212) 701-3365

Docket Number: \_\_\_\_\_

Email Address: ecarrera@cahill.com

**6. Total number of applications and registrations involved:**

17

**7. Total fee (37 CFR 2.6(b)(6) & 3.41) \$** \_\_\_\_\_

- Authorized to be charged to deposit account
- Enclosed

**8. Payment Information:**

Deposit Account Number \_\_\_\_\_

Authorized User Name \_\_\_\_\_

**9. Signature:**

Elaine Carrera

Signature

July 27, 2015

Date

Elaine Carrera

Name of Person Signing

Total number of pages including cover sheet, attachments, and document:

8

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:  
Mail Stop Assignment Recordation Branch, Director of the USPTO, P.O. Box 1450, Alexandria, VA 22313-1450

**TRADEMARK SECURITY AGREEMENT**

This **TRADEMARK SECURITY AGREEMENT**, dated as of July 24, 2015 (as it may be amended, restated, supplemented or otherwise modified from time to time, this “**Agreement**”), is made by the entity identified as a grantor on the signature page hereto (the “**Grantor**”) in favor of Barclays Bank PLC, as collateral agent for the Secured Parties (in such capacity, together with its successors and permitted assigns, the “**Collateral Agent**”).

**WHEREAS**, the Grantor is subject to, and is made party to, the Pledge and Security Agreement, dated as of June 29, 2011, as amended by the Amended and Restated Pledge and Security Agreement dated as of October 20, 2011, and as further amended by the Second Amended and Restated Pledge and Security Agreement, dated as of February 13, 2012 (as it may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “**Pledge and Security Agreement**”), between the Grantor and the other grantors party thereto and the Collateral Agent pursuant to which the Grantor granted a security interest to the Collateral Agent in the Trademark Collateral (as defined below) and are required to execute and deliver this Agreement.

**NOW, THEREFORE**, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantor hereby agrees with the Collateral Agent as follows:

**SECTION 1. Defined Terms**

Unless otherwise defined herein, terms defined in the Pledge and Security Agreement and used herein have the respective meanings given to them in the Pledge and Security Agreement.

**SECTION 2. Grant of Security Interest in Trademark Collateral**

**SECTION 2.1 Grant of Security.** The Grantor hereby grants to the Collateral Agent, for the benefit of the Secured Parties, a security interest in and continuing lien on all of the Grantor’s right, title and interest in, to and under the following, in each case whether now owned or hereafter acquired by the Grantor or in which the Grantor now has or hereafter acquires any right, title or interest and wherever the same may be located (collectively, the “**Trademark Collateral**”):

all United States and foreign trademarks, trade names, trade dress, corporate names, company names, business names, fictitious business names, Internet domain names, service marks, certification marks, collective marks, logos, other source or business identifiers, designs and general intangibles of a like nature, whether or not registered, and with respect to any and all of the foregoing: (i) all registrations and applications therefor including, without limitation, the registrations and applications listed in Schedule A attached hereto, (ii) all extensions or renewals of any of the foregoing, (iii) all of the goodwill of the business connected with the use of and symbolized by any of the foregoing, (iv) the right to sue or otherwise recover for any past, present and future infringement, dilution or other violation of any of the foregoing or for any injury to the related goodwill, (v) all Proceeds of the foregoing, including, without limitation, license fees, royalties, income, payments, claims, damages and proceeds of suit now or hereafter due and/or payable with respect thereto, and (vi) all other rights of any kind accruing thereunder or pertaining thereto throughout the world.

**SECTION 2.2 Certain Limited Exclusions.** Notwithstanding anything herein to the contrary, in no event shall the Trademark Collateral include or the security interest granted under Section 2.1 hereof attach to any Excluded Assets, including, without limitation, any “intent-to-use” application for registration of a Trademark filed pursuant to Section 1(b) of the Lanham Act, 15 U.S.C. § 1051, prior to the filing of a “Statement of Use” pursuant to Section 1(d) of the Lanham Act or an “Amendment to Allege Use” pursuant to Section 1(c) of the Lanham Act with respect thereto, solely to the extent, if any, that, and solely during the period, if any, in which, the grant of a security interest therein would impair the validity or enforceability of any registration that issues from such intent-to-use application under applicable Federal law.

### **SECTION 3. Security Agreement**

The security interest granted pursuant to this Agreement is granted in conjunction with the security interest granted to the Collateral Agent for the Secured Parties pursuant to the Pledge and Security Agreement, and the Grantor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the security interest in the Trademark Collateral made and granted hereby are more fully set forth in the Pledge and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event that any provision of this Agreement is deemed to conflict with the Pledge and Security Agreement, the provisions of the Pledge and Security Agreement shall control.

### **SECTION 4. Governing Law**

THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES THEREOF.

### **SECTION 5. Counterparts**

This Agreement may be executed in one or more counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument. Delivery of an executed counterpart to this Agreement by facsimile transmission or other electronic transmission (such as .pdf or .tif) shall be effective as delivery of a manually signed counterpart of this Agreement.

[Remainder of page intentionally left blank]

DENDREON PHARMACEUTICALS, INC.

By: *Linda A. LaGorga*  
Name: Linda A. LaGorga  
Title: Senior Vice President, Treasurer

[Signature Page to Trademark Security Agreement]

**IN WITNESS WHEREOF**, each Grantor has caused this Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Accepted and Agreed:  
**BARCLAYS BANK PLC,**  
as Collateral Agent

By: \_\_\_\_\_

Name: 

Title: **Craig Malloy**  
**Director**

[Signature Page to Trademark Security Agreement]

SCHEDULE A  
to  
TRADEMARK SECURITY AGREEMENT

TRADEMARK REGISTRATIONS AND APPLICATIONS

Jurisdiction	Trademark	App. No.	App. Date	Reg. No.	Reg. Date	Owner	Status
United States	ANTIGEN DELIVERY CASSETTE	78/651,515	6/15/2005	3,228,929	4/10/2007	Dendreon Pharmaceuticals Inc.	Registered
United States	DACS	74/681,428	5/30/1995	2,188,041	9/8/1998	Dendreon Pharmaceuticals Inc.	Registered
United States	DENDREON	75/282,526	4/29/1997	2,530,065	1/15/2002	Dendreon Pharmaceuticals Inc.	Registered
United States	DENDREON	75/283,623	4/29/1997	2,465,920	7/3/2001	Dendreon Pharmaceuticals Inc.	Registered
United States	DENDREON	76/165,904	11/9/2000	3,616,391	5/5/2009	Dendreon Pharmaceuticals Inc.	Registered
United States	Design Only	78/395,105	4/1/2004	3,581,626	2/24/2009	Dendreon Pharmaceuticals Inc.	Registered
United States	Design Only	77/463,413	5/1/2008	4,099,276	2/14/2012	Dendreon Pharmaceuticals Inc.	Registered
United States	Design Only	78/733,533	10/14/2005	3,982,430	6/21/2011	Dendreon Pharmaceuticals Inc.	Registered
United States	Design Only	78/733,522	10/14/2005	3,726,707	12/15/2009	Dendreon Pharmaceuticals Inc.	Registered
United States	INTELLIVENGE	85/780,732	11/15/2012			Dendreon Pharmaceuticals Inc.	Allowed
United States	NEUVENGE	85/657,232	6/20/2012			Dendreon Pharmaceuticals Inc.	Allowed
United States	POWERED BY INTELLIVENGE and Design	85/960,682	6/14/2013			Dendreon Pharmaceuticals Inc.	Allowed



Jurisdiction	Trademark	App. No.	App. Date	Reg. No.	Reg. Date	Owner	Status
United States	PROVENGE	75/927,064	2/23/2000	2,545,242	3/5/2002	Dendreon Pharmaceuticals Inc.	Registered
United States	THE DIFFERENCE IS PERSONAL	85/960,680	6/14/2013			Dendreon Pharmaceuticals Inc.	Allowed
United States	THE DIFFERENCE IS PERSONAL	85/960,681	6/14/2013			Dendreon Pharmaceuticals Inc.	Allowed
United States	Design Only	78/395,102	4/1/2004	3,581,625	2/24/2009	Dendreon Pharmaceuticals Inc.	Registered
United States	Design Only	77/463,424	5/1/2008	4,158,044	6/12/2012	Dendreon Pharmaceuticals Inc.	Registered
Australia	DENDREON	920752	7/24/2002	920752	3/4/2003	Dendreon Corporation	Registered
Canada	DENDREON	1148456	7/30/2002	TMA799,137	6/2/2011	Dendreon Corporation	Registered
Canada	Design Only	1685568	7/16/2014			Dendreon Corporation	Office Action Issued
Canada	PROVENGE	1537312	7/27/2011	TMA848,037	4/9/2013	Dendreon Corporation	Registered
China	DENDREON	3338807	10/17/2002	3338807	5/7/2004	Dendreon Corporation	Registered
China	DENDREON	3462760	2/20/2003	3462760	9/21/2004	Dendreon Corporation	Registered
European Community	DENDREON	2786317	7/24/2002	2786317	1/21/2004	Dendreon Corporation	Registered
European Community	Design Only	3919081	7/12/2004	3919081	11/16/2005	Dendreon Corporation	Registered
European Community	PROVENGE	1816974	8/21/2000	1816974	10/5/2001	Dendreon Corporation	Registered
European Community	Design Only	3919073	7/12/2004	3919073	11/16/2005	Dendreon Corporation	Registered
Hong Kong	DENDREON	2002 11420	7/24/2002	200316300	12/30/2003	Dendreon Corporation	Registered
Ireland	DENDREON	02/1488	7/25/2002	225773	6/30/2003	Dendreon Corporation	Registered
Japan	DENDREON	2002-071245	8/22/2002	4748818	2/20/2004	Dendreon Corporation	Registered
Japan	Design Only	82921/2004	9/8/2004	4844098	3/4/2005	Dendreon Corporation	Registered
Japan	Design Only	82922/2004	9/8/2004	4854919	4/8/2005	Dendreon Corporation	Registered
Japan	Design Only	65404/2004	7/14/2004	4844005	3/4/2005	Dendreon Corporation	Registered
Japan	PROVENGE	2002-046880	6/6/2002	4655127	3/20/2003	Dendreon Corporation	Registered

TRADEMARK

REEL: 005585 FRAME: 0453

Jurisdiction	Trademark	App. No.	App. Date	Reg. No.	Reg. Date	Owner	Status
Japan	Design Only	65401/2004	7/14/2004	4825474	12/10/2004	Dendreon Corporation	Registered
Japan	Design Only	65402/2004	7/14/2004	4844004	3/4/2005	Dendreon Corporation	Registered
New Zealand	DENDREON	661517	7/29/2002	661517	3/3/2003	Dendreon Corporation	Registered
New Zealand	DENDREON	664161	9/9/2002	664161	3/13/2003	Dendreon Corporation	Registered
Norway	DENDREON	200206940	7/26/2002	218776	5/2/2003	Dendreon Corporation	Registered
Republic of Korea	DENDREON	40-02-34025	7/25/2002	40-0575330	2/23/2004	Dendreon Corporation	Registered
Switzerland	DENDREON	06607/2002	7/26/2002	507918	3/4/2003	Dendreon Corporation	Registered

TRADEMARK